Teva’s New Copaxone Gaining Market Share Ahead Of Generics
This article was originally published in The Pink Sheet Daily
With the imminent possibility of generic competition to Copaxone, Teva looks to move 65% of current patients to its thrice-weekly version by the end of 2014.
You may also be interested in...
Teva appears to have eased past a management shakeup and extended its lead in Copaxone with the company ready to expand in emerging markets as the next frontier, led by Russia and Latin America.
Wall Street is mixed on whether Teva’s newly approved three-times-weekly formulation will protect its MS blockbuster franchise.
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.